Coronary Heart Disease Clinical Trials

Find Coronary Heart Disease Clinical Trials Near You

Drug-Coated Balloon in Anticoagulated and Bleeding Risk Patients Undergoing PCI

Status: Recruiting
Location: See all (14) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The purpose of this study is to compare DCB with DES in stable CAD or ACS patients who are at high risk of bleeding. The hypothesis of the DEBATE trial is that the strategy using DCB and a shorter DAPT regimen is non-inferior to the treatment using DES and longer DAPT duration on patients with high bleeding risk. If non-inferiority is shown, the superiority of the DCB strategy over DES strategy will be tested.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥ 18 years

• Informed written consent

• At least one major or two minor bleeding risk criteria of Academic Research Consortium (ARC)

‣ Major Criteria

• Long-term oral anticoagulation

• Severe or end stage chronic kidney disease (CKD) (estimated glomerular - filtration rate \[eGFR\] \<30 ml/min)

• Hemoglobin \<110 g/l

• Spontaneous bleeding requiring hospitalization and transfusion in the past 6 months

• Moderate to severe baseline thrombocytopenia (platelet count \<100 x 10e9/L)

• Chronic bleeding diathesis

• Liver cirrhosis with portal hypertension

• Active cancer in the past 12 months

• Previous spontaneous ICH (at any time)

• Previous traumatic ICH within the past 12 months

• Presence of known brain arteriovenous malformation

• Moderate to severe ischemic stroke within the past 6 months

• Nondeferrable major surgery on dual antiplatelet therapy

• Recent major surgery or trauma within 30 days before PCI

‣ Minor Criteria

• Age \>75 years

• Moderate CKD (eGFR 30-59 ml/min)

• Hemoglobin 110-129 g/l for men and 110-119 g/l for women

• Spontaneous bleeding requiring hospitalization or transfusion within the past 12 - months not meeting major criterion

• Long term use of oral nonsteroidal antiinflammatory drugs or steroids

• Any ischemic stroke at any time not meeting major criterion

‣ Either of the following:

⁃ Stabile angina or dyspnea and a coronary narrowing causing myocardial ischemia detected in the angiogram. In stable patients prior PCI, the evidence of ischemia is needed acquired either by perfusion imaging or by pressure wire measurement (FFR) during coronary angiography unless the coronary stenosis is \> 90% in diameter.

⁃ ACS (UAP or NSTEMI): symptoms of heart ischemia≥ 20 minutes and ≥ 0,5mm ST-depression or transient ST-elevation or T-wave inversion at least in two adjacent leads and/or a high sensitivity troponin (hs-tnt) rise at least one unit above the 99. percentil or at least 50% rise in hs-tnt between two samples taken 1-3 hours apart.

‣ At least one of the following:

• ≥1 de novo lesions in native coronary arteries or bypass vein grafts

• Reference diameter of the vessel is 2.0-5.0mm'

• Lesion length ≤ 40mm

• Lesion or lesions are suitable for PCI

Locations
Other Locations
Finland
Helsinki University Hospital
NOT_YET_RECRUITING
Helsinki
North Karelia Central Hospital
RECRUITING
Joensuu
Central Hospital of Central Finland
NOT_YET_RECRUITING
Jyväskylä
Kuopio University Hospital
NOT_YET_RECRUITING
Kuopio
Central Hospital of Päijät-Häme
RECRUITING
Lahti
Oulu university hospital
NOT_YET_RECRUITING
Oulu
Satakunta Central Hospital
NOT_YET_RECRUITING
Pori
Central Hospital of Lapland
NOT_YET_RECRUITING
Rovaniemi
Tampere Heart Hospital
NOT_YET_RECRUITING
Tampere
Turku University Hospital
NOT_YET_RECRUITING
Turku
France
Centre Hospitalier La Rochelle
NOT_YET_RECRUITING
La Rochelle
Germany
University Hospital of Carl Gustav Carus
NOT_YET_RECRUITING
Dresden
University Hospital of Saarland
NOT_YET_RECRUITING
Homburg
United Kingdom
Norfolk and Norwich University Hospital Nhs Foundation Trust
NOT_YET_RECRUITING
Norwich
Contact Information
Primary
Tuomas Rissanen, MD, PhD
tuomas.rissanen@siunsote.fi
+358505998022
Backup
Alma Räsänen, MD
alma.rasanen@siunsote.fi
Time Frame
Start Date: 2022-09-01
Estimated Completion Date: 2028-01-01
Participants
Target number of participants: 546
Treatments
Experimental: Drug-coated balloon (DCB)
The coronary lesions fulfilling the inclusion criteria and randomized to the DCB group.
Active_comparator: Drug-eluting stent (DES)
The coronary lesions fulfilling the inclusion criteria and randomized to the DES group.
Authors
Alma Toivonen
Sponsors
Collaborators: Oulu University Hospital, Tampere University Hospital, Norfolk and Norwich University Hospitals NHS Foundation Trust, Central Finland Hospital District, Central Hospital of Lapland, Helsinki University Central Hospital, University Hospital, Saarland, Centre Hospitalier de La Rochelle, University Hospital Carl Gustav Carus, Hospital Universitario de Cabuenes, Päijät Häme Central Hospital, Turku University Hospital, Satakunta Central Hospital, Kuopio University Hospital
Leads: North Karelia Central Hospital

This content was sourced from clinicaltrials.gov